<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646072</url>
  </required_header>
  <id_info>
    <org_study_id>20148-494</org_study_id>
    <nct_id>NCT02646072</nct_id>
  </id_info>
  <brief_title>Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients</brief_title>
  <official_title>The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there is a relationship between
      inflammatory cytokines in the aqueous of the eye and thickness of the macula after treatment
      of topical ketorolac for patients undergoing cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare aqueous levels of inflammatory cytokines in diabetic and non diabetic patients
      treated with preoperative topical ketorolac tromethamine 0.45%.

      To compare the macular thickness changes in diabetic and non diabetic patients treated with
      preoperative ketorolac tromethamine 0.45% and its correlation with the aqueous inflammatory
      cytokines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of aqueous inflammatory cytokines post treatment as assessed using Bio-plex Pro Assays</measure>
    <time_frame>9 months</time_frame>
    <description>Aqueous samples were analyzed at the same after complete samples collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in central subfield retinal thickness as assessed by optical coherence tomography</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Cystoid Macular Edema, Postoperative</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Diabetes mellitus patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes mellitus control patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Topical refresh plus four times a day for 3 days prior to cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non diabetic patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non diabetic control patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Topical refresh plus four times a day for 3 days prior to cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac tromethamine ophthalmic solution 0.45%</intervention_name>
    <description>Indicated for the treatment of pain and inflammation following cataract surgery.</description>
    <arm_group_label>Diabetes mellitus patients</arm_group_label>
    <arm_group_label>Non diabetic patients</arm_group_label>
    <other_name>Acuvail</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diabetic patient group

          1. Type 2 diabetes mellitus with no diabetic retinopathy

          2. If with co-morbid, controlled hypertension with no hypertensive crisis in recent six
             months

          3. Listed for phacoemulsification cataract surgery

        Non diabetic patient group

          1. No history of diabetes

          2. If with co-morbid, controlled hypertension with no hypertensive crisis in recent six
             months

          3. Listed for phacoemulsification cataract surgery

        Exclusion Criteria:

          1. Smoker

          2. Presence of immune disease, local or systemic inflammation

          3. Presence of retinal diseases, glaucoma

          4. Previous surgical procedure on the eye

          5. Intra-operative complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yin Peng Lai, MOphthal</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammadreza Peyman, Mophthal</last_name>
    <role>Study Chair</role>
    <affiliation>University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tajunisah Iqbal, FRCS Ophth</last_name>
    <role>Study Director</role>
    <affiliation>University of Malaya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Malaya</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <reference>
    <citation>Cheung CM, Vania M, Ang M, Chee SP, Li J. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol Vis. 2012;18:830-7. Epub 2012 Apr 4.</citation>
    <PMID>22511846</PMID>
  </reference>
  <reference>
    <citation>Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013 Aug 4;19:1734-46. Print 2013.</citation>
    <PMID>23922491</PMID>
  </reference>
  <reference>
    <citation>Chu L, Wang B, Xu B, Dong N. Aqueous cytokines as predictors of macular edema in non-diabetic patients following uncomplicated phacoemulsification cataract surgery. Mol Vis. 2013 Nov 24;19:2418-25. eCollection 2013.</citation>
    <PMID>24319335</PMID>
  </reference>
  <reference>
    <citation>Yilmaz T, Cordero-Coma M, Gallagher MJ. Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. Eye (Lond). 2012 Feb;26(2):252-8. doi: 10.1038/eye.2011.296. Epub 2011 Nov 18. Review.</citation>
    <PMID>22094296</PMID>
  </reference>
  <reference>
    <citation>Schoenberger SD, Kim SJ, Sheng J, Calcutt MW. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. JAMA Ophthalmol. 2014 Feb;132(2):150-4. doi: 10.1001/jamaophthalmol.2013.5692.</citation>
    <PMID>24264034</PMID>
  </reference>
  <reference>
    <citation>Schoenberger SD, Kim SJ, Shah R, Sheng J, Cherney E. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. JAMA Ophthalmol. 2014 Jan;132(1):32-7. doi: 10.1001/jamaophthalmol.2013.6203.</citation>
    <PMID>24336915</PMID>
  </reference>
  <reference>
    <citation>Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007 Sep;33(9):1550-8.</citation>
    <PMID>17720069</PMID>
  </reference>
  <reference>
    <citation>Almeida DR, Johnson D, Hollands H, Smallman D, Baxter S, Eng KT, Kratky V, ten Hove MW, Sharma S, El-Defrawy S. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J Cataract Refract Surg. 2008 Jan;34(1):64-9. doi: 10.1016/j.jcrs.2007.08.034.</citation>
    <PMID>18165083</PMID>
  </reference>
  <reference>
    <citation>Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M; Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008 Oct;146(4):554-560. doi: 10.1016/j.ajo.2008.04.036. Epub 2008 Jul 2.</citation>
    <PMID>18599019</PMID>
  </reference>
  <reference>
    <citation>Bucci FA Jr, Waterbury LD. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Curr Med Res Opin. 2011 Dec;27(12):2235-9. doi: 10.1185/03007995.2011.626018. Epub 2011 Oct 12.</citation>
    <PMID>21992076</PMID>
  </reference>
  <reference>
    <citation>Heier JS, Awh CC, Busbee BG, Waterbury LD, Daniel P, Stoller GL, Cleary TS. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina. 2009 Oct;29(9):1310-3. doi: 10.1097/IAE.0b013e3181b094e6.</citation>
    <PMID>19934822</PMID>
  </reference>
  <reference>
    <citation>Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis. 2009 Sep 19;15:1906-14.</citation>
    <PMID>19784389</PMID>
  </reference>
  <reference>
    <citation>Hanifi-Moghaddam P, Kappler S, Seissler J, Müller-Scholze S, Martin S, Roep BO, Strassburger K, Kolb H, Schloot NC. Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus. Diabet Med. 2006 Feb;23(2):156-63.</citation>
    <PMID>16433713</PMID>
  </reference>
  <reference>
    <citation>Oh IK, Kim SW, Oh J, Lee TS, Huh K. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res. 2010 Dec;35(12):1116-27. doi: 10.3109/02713683.2010.510257.</citation>
    <PMID>21121809</PMID>
  </reference>
  <reference>
    <citation>Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK; Diabetic Retinopathy Clinical Research Network. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol. 2008 May;145(5):894-901. doi: 10.1016/j.ajo.2007.12.025. Epub 2008 Feb 21.</citation>
    <PMID>18294608</PMID>
  </reference>
  <reference>
    <citation>Gharbiya M, Cruciani F, Cuozzo G, Parisi F, Russo P, Abdolrahimzadeh S. Macular thickness changes evaluated with spectral domain optical coherence tomography after uncomplicated phacoemulsification. Eye (Lond). 2013 May;27(5):605-11. doi: 10.1038/eye.2013.28. Epub 2013 Mar 1.</citation>
    <PMID>23449512</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaya</investigator_affiliation>
    <investigator_full_name>Lai Yin Peng, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>aqueous humor</keyword>
  <keyword>inflammatory cytokines</keyword>
  <keyword>cystoid macular edema, postoperative</keyword>
  <keyword>nonsteroidal anti-inflammatory drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

